Chemotherapy in head and neck cancer

Merlano, Marco; Benasso, Marco; Cavallari, Monica; Blengio, F.; Rosso, M.

doi:10.1016/0964-1955(94)90026-4

Cited by 13 publications

(3 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Induction chemotherapy is now well recognized as a first step in an integrated treatment program for aggressive or locally advanced head and neck malignant tumors [14,23]. There is also clear evidence that direct administration of most cytotoxic agents into the local arterial blood supply can achieve a greater tumor exposure to the drug, with the potential for reduced systemic toxicity [1,24].…”

Section: Introductionmentioning

confidence: 99%

Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer

Benazzo¹,

Caracciolo²,

Zappoli

et al. 2000

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

To evaluate the feasibility, maximum dose of drug tolerated, technical problems, systemic and local toxicity, response rate, overall and disease-free survival, we studied superselective intra-arterial infusion of high-dose carboplatin as part of a multimodality treatment for head and neck cancer. Forty patients with untreated stage II-IV head and neck squamous cell carcinomas received induction chemotherapy with high-dose carboplatin (three cycles at 2-week intervals using 300-350 mg/m2 per cycle), delivered via superselective transfemoral angiography followed by radiotherapy or surgery plus radiotherapy. No technical complications occurred during or after the infusion. Systemic toxicity was minimal, and local toxicity was moderate. At the end of chemotherapy the overall complete and partial response rate was 90% (36/40) at the primary site and 64% (16/25) at the neck nodes. The median follow-up was 24.4 months (range 3-52). To date 21 patients are alive without disease, 2 are alive with disease, 13 have died of disease, and 4 have developed a metachronous lung tumor. There was a good correlation between the response to chemotherapy and disease-free survival. No statistically significant benefit in survival was observed with respect to other series of head and neck tumors treated with different protocols. However, discriminating between responding and nonresponding patients, this procedure can have a prognostic significance in planning integrated treatments for these types of tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer

Benazzo¹,

Caracciolo²,

Zappoli

et al. 2000

European Archives of Oto-Rhino-Laryngology

View full text Add to dashboard Cite

show abstract

“…Methotrexate (MTX) is a frequently used chemotherapeutic agent against different cancer types, including colon, breast, skin, and head and neck cancer. [ 102–104 ] Formulating effective delivery strategies can reduce the toxic side effects of MTX. For instance, a mucoadhesive patch based on MTX‐loaded liposomes (M‐LP) for the local delivery of methotrexate (MTX) in oral cancer treatment can lower the toxic effects of MTX.…”

Section: Mucoadhesive Polymers For Oral Cancermentioning

confidence: 99%

Beyond traditional therapy: Mucoadhesive polymers as a new frontier in oral cancer management

et al. 2023

View full text Add to dashboard Cite

In recent times mucoadhesive drug delivery systems are gaining popularity in oral cancer. It is a malignancy with high global prevalence. Despite significant advances in cancer therapeutics, improving the prognosis of late‐stage oral cancer remains challenging. Targeted therapy using mucoadhesive polymers can improve oral cancer patients' overall outcome by offering enhanced oral mucosa bioavailability, better drug distribution and tissue targeting, and minimizing systemic side effects. Mucoadhesive polymers can also be delivered via different formulations such as tablets, films, patches, gels, and nanoparticles. These polymers can deliver an array of medicines, making them an adaptable drug delivery approach. Drug delivery techniques based on these mucoadhesive polymers are gaining traction and have immense potential as a prospective treatment for late‐stage oral cancer. This review examines leading research in mucoadhesive polymers and discusses their potential applications in treating oral cancer.

show abstract

“…Additionally, this study group identified that the downregulation of matrix metalloproteinase 2 and receptor tyrosine-protein kinase ErbB-2 gene expression in an OSCC rat model were responsible for the clinical outcomes observed (17,18). MTX is a commonly used anticancer agent for various types of cancer, including colon, breast, skin and head and neck cancer (19)(20)(21). Due to the high toxicity of MTX, various strategies have been attempted to formulate an effective delivery of MTX with reduced side effects.…”

Section: Introductionmentioning

confidence: 99%

Development and inï¿½vitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer

Jin

Dong

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. The present study focused on the development of a mucoadhesive patch of methotrexate (MTX) for targeted delivery in oral cancer. Initially, MTX-loaded liposomes were prepared using the thin film hydration method, and had a mean diameter of 105.7-137.4 nm and percentage entrapment efficiency of 54.6±3.5. These liposomes were cast in optimized mucoadhesive film. The film was characterized by its release pattern, thickness, weight and percentage swelling index and the sustained release profile of the optimized film was evaluated. The developed liposomes and liposomes cast in the film formulation were evaluated for cytotoxicity in HSC-3 cells using an MTT assay, and a significant decrease in the half maximal inhibitory concentration of MTX was identified with the MTX-entrapped liposomal film, M-LP-F7. The results of the mitochondria-dependent intrinsic pathway demonstrated that there was significant mitochondrial membrane potential disruption with M-LP-F7 compared with the plain drug. M-LP-F7 increased the rate of apoptosis in HSC-3 cells by almost 3-fold. Elevated levels of reactive oxygen species provided evidence that M-LP-F7 exerts a pro-oxidant effect in HSC-3 cells.

show abstract

Chemotherapy in head and neck cancer

Cited by 13 publications

References 47 publications

Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer

Induction chemotherapy by superselective intra-arterial high-dose carboplatin infusion for head and neck cancer

Beyond traditional therapy: Mucoadhesive polymers as a new frontier in oral cancer management

Development and inï¿½vitro evaluation of mucoadhesive patches of methotrexate for targeted delivery in oral cancer

Contact Info

Product

Resources

About